nach oben

Surgery Today

Erschienen in:

01.09.2014 | Review Article

Ischemia–reperfusion injury in patients with fatty liver and the clinical impact of steatotic liver on hepatic surgery

verfasst von: Hirotaka Tashiro, Shintaro Kuroda, Yoshihiro Mikuriya, Hideki Ohdan

Erschienen in: Surgery Today | Ausgabe 9/2014

Einloggen, um Zugang zu erhalten

Abstract

Hepatic steatosis is one of the most common hepatic disorders in developed countries. The epidemic of obesity in developed countries has increased with its attendant complications, including metabolic syndrome and non-alcoholic fatty liver disease. Steatotic livers are particularly vulnerable to ischemia/reperfusion injury, resulting in an increased risk of postoperative morbidity and mortality after liver surgery, including liver transplantation. There is growing understanding of the molecular and cellular mechanisms and therapeutic approaches for treating ischemia/reperfusion injury in patients with steatotic livers. This review discusses the mechanisms underlying the susceptibility of steatotic livers to ischemia/reperfusion injuries, such as mitochondrial dysfunction and signal transduction alterations, and summarizes the clinical impact of steatotic livers in the setting of hepatic resection and liver transplantation. This review also describes potential therapeutic approaches, such as ischemic and pharmacological preconditioning, to prevent ischemia/reperfusion injury in patients with steatotic livers. Other approaches, including machine perfusion, are also under clinical investigation; however, many pharmacological approaches developed through basic research are not yet suitable for clinical application.

Kleiner DE, Brunt EM, Natta MV, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–21.PubMed

Szczepaniak LS, Nurenberg P, Leonard D, Browning JD, Reingold JS, Grundy S, et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab. 2005;288:E462–8.PubMed

Chittu S, Farrell GC, Hashimoto E, Saibara T, Lau GK, Sollano JD. Non-alcoholic fatty liver disease in the Asia-Pacific region: definitions and overview of proposed guidelines. J Gastroenterol Hepatol. 2007;22:778–87.

Amarapurkar DN, Hashimoto E, Lesmana LA, Sollano JD, Chen PJ, Goh KL. How common is non-alcoholic fatty liver disease in the Asia-Pacific region and are there local differences? J Gastroenterol Hepatol. 2007;22:788–93.PubMed

Petrowsky H, McCormack L, Trujillo M, Selzner M, Jochum W, Clavian PA. A prospective, randomized, controlled trial comparing intermittent portal triad clamping versus ischemic preconditioning with continuous clamping for major liver resection. Ann Surg. 2006;244:921–8.PubMedCentralPubMed

Angulo P. Nonalcoholic fatty liver disease and liver transplantation. Liver Transpl. 2006;12(523–534):5.

McCormack L, Petrowsky H, Jochum W, Furrer K, Clavien PA. Hepatic steatosis is a risk factor for postoperative complications after major hepatectomy: a matched case–control study. Ann Surg. 2007;245:923–30.PubMedCentralPubMed

Gomez D, Malik HZ, Bonney GK, Wong V, Toogood GJ, Lodge JP, et al. Steatosis predicts postoperative morbidity following hepatic resection for colorectal metastasis. Br J Surg. 2007;94:1395–402.PubMed

Trevisani F, Colantoni A, Caraceni P, Van Thiel DH. The use of donor fatty liver for liver transplantation: a challenge or a quagmire? J Hepatol. 1996;24:114–21.PubMed

10.

Hui AM, Kawasaki S, Makuuchi M, Nakayama J, Ikegami T, Miyagawa S. Liver injury following normothermic ischemia in steatotic rat liver. Hepatology. 1994;20:1287–93.PubMed

11.

Wada K, Fujimoto K, Fujikawa Y, Shibayama Y, Mitsui H, Nakata K. Sinusoidal stenosis as the cause of portal hypertension in choline deficient diet induced fatty cirrhosis of the rat liver. Acta Pathol Jpn. 1974;24:207–17.PubMed

12.

Caraceni P, Ryu HS, Subbotin V, De Maria N, Colantoni A, Roberts L, et al. Rat hepatocytes isolated from alcohol-induced fatty liver have an increased sensitivity to anoxic injury. Hepatology. 1997;25:943–9.PubMed

13.

Nanashima A, Abo T, Hamasaki K, Wakata K, Kunizaki M, Tou K, et al. Predictors of intraoperative blood loss in patients undergoing hepatectomy. Surg Today. 2013;43:485–93.PubMed

14.

Lentsch A, kato A, Yoshidome H, McMasters K, Edwards M. Inflammatory mechanisms and therapeutic strategies for warm hepatic ischemia/reperfusion. Hepatology. 2000;32:169–73.PubMed

15.

Selzner M, Rudiger HA, Sindram D, Madden J, Clavien PA. Mechanisms of ischemic injury are different in the steatotic and normal rat liver. Hepatology. 2000;32:1280–8.PubMed

16.

Malhi H, Gores G, Lemasters JJ. Apoptosis and necrosis in the liver: a tale of two deaths? Hepatology. 2006;43:S31–44.PubMed

17.

Selzner N, Selzner M, Jochum W, Amann-Vesti B, Graf R, Clavien PA. Mouse livers with macrosteatosis are more susceptible to normothermic ischemic injury than those with microsteatosis. J Hepatol. 2006;44:694–701.PubMed

18.

Vetelaninen R, Van Vliet A, Gouma DJ, Van Gulik TM. Steatosis as a risk factor in liver surgery. Ann Surg. 2007;245:20–30.

19.

Caraceni P, Bianchi C, Domenicali M, Pertosa AM, Maiolini E, Parenti G, et al. Impairment of mitochondrial oxidative phosphorylation in rat fatty liver exposed to preservation-reperfusion injury. J Hepatol. 2004;41:82–8.PubMed

20.

Echtay K, Winkler E, Frischmuth K, Klingenberg M. Uncoupling protein 2 and 3 are highly active H+ transporters and highly nucleotide sensitive when activated by coenzyme Q (ubiquinone). Proc Natl Acad Sci USA. 2001;98:1416–21.PubMedCentralPubMed

21.

Echtay K, Roussel D, St-Pierre J, Jekabsons MB, Cadenas S, Stuart JA, et al. Nature. 2002;415:96–9.PubMed

22.

Cortez-Pinto H, Lin HZ, Yang SQ, Costa SOD, Diehl AM. Lipids up-regulate uncoupling protein 2 expression in rat hepatocytes. Gastroenterology. 1999;116:1184–93.PubMed

23.

Rashid A, Wu TC, Huang CC, Chen CH, Lin HZ, Yang SQ, et al. Mitochondrial proteins that regulate apoptosis and necrosis are induced in mouse fatty liver. Hepatology. 1999;29:1131–8.PubMed

24.

Chavin KD, Yang SQ, Lin HZ, Chatham J, Chacko VP, Hoek JB, et al. Obesity induces expression of uncoupling protein-2 in hepatocytes and promotes liver ATP depletion. J Biol Chem. 1999;274:5692–700.PubMed

25.

Evans ZP, Ellett JD, Schmit MG, Schnellmann RG, Chavin KD. Mitochondrial uncoupling protein-2 mediates steatotic liver injury following ischemia/reperfusion. J Biol Chem. 2008;283:8573–9.PubMedCentralPubMed

26.

Serviddio G, Bellanti F, Tamborra R, Rollo T, Capitanio N, Romano AD, et al. Uncoupling protein-2 (UCP2) induces mitochondrial proton leak and increases susceptibility of non-alcoholic steatohepatitis (NASH) liver to ischemia–reperfusion injury. Gut. 2008;57:957–65.PubMed

27.

Chavin KD, Fiorini RN, Shafizadeh S, Cheng G, Wan C, Evans Z, et al. Fatty acid synthase blockade protects steatotic livers from warm ischemia reperfusion injury and transplantation. Am J Transpl. 2004;4:1440–7.

28.

Fiorini RN, Donovan JL, Rodwell D, Evans Z, Cheng G, May HD, et al. Short-term administration of (−)-epigallocatechin gallate reduces hepatic steatosis and protects against warm hepatic ischemia/reperfusion injury in steatotic mice. Liver Transpl. 2005;11:298–308.PubMed

29.

Tolba RH, Putz U, Decker D, Dombrowski F, Lauschke H. l-Carnitine ameliorates abnormal vulnerability of steatotic rat livers to cold ischemic preservation. Transplantation. 2003;76:1681–6.PubMed

30.

Dara L, Ji C, Kaplowitz N. The contribution of endoplasmic reticulum stress to liver diseases. Hepatology. 2011;53:1752–63.PubMedCentralPubMed

31.

Tiriveedhi V, Conzen KD, Lian-Conlin JL, Upadhya G, Malone J, Townsend RR, et al. The role of molecular chaperons in warm ischemia and reperfusion injury in the steatotic liver: a proteomic study. BMC Biochem. 2012;13:17–26.PubMedCentralPubMed

32.

Mosbah IB, Alfany-Fernandez I, Martel C, Zaouali MA, Bintanel-Morcillo M, Rimola A, et al. Endoplasmic reticulum stress inhibition protects steatotic and non-steatotic livers in partial hepatectomy under ischemia–reperfusion. Cell Death Dis. 2010;1:e52.PubMedCentralPubMed

33.

Anderson CD, Upadhya G, Conzen KD, Jia J, Brunt EM, Tiriveedhi V, et al. Endoplasmic reticulum stress is a mediator of posttransplant injury in severely steatotic liver allografts. Liver Transpl. 2011;17:189–200.PubMedCentralPubMed

34.

Elias-Miro M, Jimenez-Castro MB, Mendes-Braz M, Casillas-Ramirez A, Peralta C. The current knowledge of the role of PPAR in hepatic ischemia–reperfusion injury. PPAR Res. 2012;2012:802384.

35.

Pettinelli P, del Pozo T, Araya J, Rodrigo R, Araya AV, Smok G, et al. Enhancement in liver SREBP-1c/PPAR-α ratio and steatosis in obese patients: correlations with insulin resistance and n-3 long-chain polyunsaturated fatty acid depletion. Biochim Biophys Acta. 2009;1792:1080–6.PubMed

36.

Pettineli O, Videla LA. Up-regulation of PPAR-γ mRNA expression in the liver of obese patients: an additional reinforcing lipogenic mechanism to SREBP-1c induction. J Clin Endocrin Metabol. 2011;96:1424–30.

37.

Teoh NC, Williams J, Hartley J, Yu J, McCuskey RS, Farrell GC. Short-term therapy with peroxisome proliferation-activator receptor-α agonist wy-14,643 protects murine fatty liver agonist ischemia–reperfusion injury. Hepatology. 2010;51:996–1006.PubMed

38.

Massip-Salcedo M, Zaouali MA, Padrissa-Altes S, Casillas-Ramirez A, Rodes J, Rosello-Catafau J, et al. Activation of peroxisome proliferators-activated receptor-αinhibits the injurious effects of adiponectin in rat steatotic liver undergoing ischemia–reperfusion. Hepatology. 2008;47:461–72.PubMed

39.

Elias-Miro M, Massip-Salcedo M, Jimenez-Castro M, Peralta C. Does adiponectin benefit steatotic liver transplantation? Liver Transpl. 2011;17:993–1004.PubMed

40.

Mosbath IB, Rosello-Catafau J, Franco-Gou R, Abdennebi HB, Saidane D, Ramella-Virieux S, et al. Preservation of steatotic livers in IGL-1 solution. Liver Transpl. 2006;12:1215–23.

41.

Zaouali MA, Reiter RJ, Padrissa-Altes S, Boncompagni E, Garcia JJ, Ben Abnennebi H, et al. Melatonin protects steatotic and nonsteatotic liver grafts against cold ischemia and reperfusion injury. J Pineal Res. 2011;50:213–21.PubMed

42.

Man K, Zhao Y, Xu A, Lo CM, Lam KSL, Ng KT, et al. Fat-derived hormone adiponectin combined with FTY720 significantly improves small-for-size fatty liver graft survival. Am J Transpl. 2006;6:467–76.

43.

Elias-Miro M, Massip-Salcedo M, Jimenez-Castro M, Peralta C. Does adiponectin benefit steatotic liver transplantation? Liver Transpl. 2011;17:993–1004.PubMed

44.

Casillas-Ramirez A, Amine-Zaouali M, Massip-Salcedo M, Padrissa-Altes S, Bintanel-Morcillo M, Ramalho F, et al. Inhibition of angiotensin II action protects rat steatotic livers against ischemia–reperfusion injury. Crit Care Med. 2008;36:1256–66.PubMed

45.

Casillas-Ramirez A, Zaouali A, Padrissa-Altes S, Ben MI, Pertosa A, Alfany-Fernandez I, et al. Insulin-like growth factor and epidermal growth factor tretament: new approaches to protecting ateatotic livers against ischemia–reperfusion injury. Endocrinology. 2009;150:3153–61.PubMedCentralPubMed

46.

Casillas-Ramirez A, Alfany-Fernandez I, Massip-Salcedo M, Juan ME, Planas JM, Serafin A, et al. Retinol-binding protein 4 and peroxisome proliferatior-activated receptor-γin steatotic liver transplantation. J Parmacol Exp Ther. 2011;338:143–53.

47.

Jimenez-Castro MB, Elias-Miro M, Mendes-Braz M, Lemoine A, Rimola A, Rodes J, et al. Tauroursodeoxycholic acid affects PPARγ and TLR4 in steatotic liver transplantation. Am J Transpl. 2012;12:3257–71.

48.

Alfany-Fernandez I, Casillas-Ramirez A, Bintanel-Morcillo M, Brosnihan KB, Ferrario CM, Serafin A, et al. Therapeutic targets in liver transplantation: angiotensin II in nonsteatotic grafts and angiotensin-(1–7) in steatotic grafts. Am J Transplt. 2009;9:439–51.

49.

Ellett JD, Evans ZP, Atkinson C, Schmidt MG, Schnellmann RG, Chavin KD. Toll-like receptor 4 is a key mediator of murine steatotic liver warm ischemia/reperfusion injury. Liver Transpl. 2009;15:1101–9.PubMedCentralPubMed

50.

Firorini RN, Shafizadeh SF, Polito C, Rodwell DW, Cheng G, Evans Z, et al. Anti-endotoxin monoclonal antibodies are protective against hepatic ischemia/reperfusion injury in steatotic mice. Am J Transpl. 2004;4:1567–73.

51.

Zaouali MA, Bardag-Gorce FB, Carbonell T, Oliva J, Pantazi E, Bejaoui M, et al. Proteasome inhibitors protect the steatotic and non-steatotic liver graft against cold ischemia reperfusion injury. Exp Mol Path. 2013;94:352–9.

52.

He S, Atkinson C, Evans Z, Ellett JD, Southwood M, Elvington A, et al. A role for compliment in the enhanced susceptibility of steatotic livers to ischemia and reperfusion injury. J Immunol. 2009;183:4764–72.PubMed

53.

Selzner N, Selzner M, Jochum W, Clavian PA. Ischemic preconditioning protects the steatotic mouse liver against reperfusion injury: an ATP dependent mechanism. J Hepatology. 2003;39:55–61.

54.

Rolo AP, Teodoro JS, Peralta C, Rosello-catafau JR, Palmeira CM. Prevention of I/R injury in fatty livers by ischemic preconditioning is associated with increased mitochondrial tolerance: the key role of ATP synthase and mitochondrial permeability transition. Transpl Int. 2009;22:1081–90.PubMed

55.

Serafin A, Rosello-Catafau J, Prats N, Xaus C, Gelpi E, Peralta C. Ischemic preconditioning increases the tolerance of fatty liver to hepatic ischemia–reperfusion injury in the rat. Am J Pathol. 2002;161:587–601.PubMedCentralPubMed

56.

Yamagami K, Yamamoto Y, Kume M, Kimoto S, Yamamoto H, Ozaki N, et al. Heat shock preconditioning ameliorates liver injury following normothermic ischemia–reperfusion in steatotic rat livers. J Surg Res. 1998;79:47–53.PubMed

57.

Massip-Salcedo M, Casillas-Ramirez A, Franco-Gou R, Ben Mosban I, Serafin A, et al. Heat shock proteins and mitogen-activated protein kinases in steatotic livers undergoing ischemia–reperfusion: some answers. Am J Pathol. 2006;168:1474–85.PubMedCentralPubMed

58.

Bouma HR, Ketelaar ME, Yard BA, Pleoeg RJ, Henning RH. AMP-activated protein kinase as a target for preconditioning in transplantation medicine. Transplantation. 2010;90:353–8.PubMed

59.

Carrasco-Chaumel E, Rosello-Catafau J, Bartrons R, Franco-Gou R, Xaus C, Casillas A, et al. Adenosine monophosphate-activated protein kinase and nitric oxide in rat steatotic liver transplantation. J Hepatol. 2005;43:997–1006.PubMed

60.

Serafin A, Rosello-Catafau J, Prats N, Gelpi E, Rodes J, Peralta C. Ischemic preconditioning affects interleukin release in fatty livers of rats undergoing ischemia/reperfusion. Hepatology. 2004;39:688–98.PubMed

61.

Tacchini L, Cario G, De Ponti C, Massip M, Rosello-Catafau J, Peralta C. Up regulation of IL-6 by ischemic preconditioning in normal and fatty rat livers: association with reduction of oxidative stress. Free Radic Res. 2006;40:1206–17.PubMed

62.

Sun Z, Klein AS, Radaeva S, Hong F, EL-Assal O, Pan HN, et al. In vitro interleukin-6 treatment prevents mortality associated with fatty liver transplants in rats. Gastroenterology. 2003;125:202–15.PubMed

63.

Hong F, Radaeva S, Pan HN, Tian Z, Veech R, Gao B. Interleukin 6 alleviates hepatic steatosis and ischemia/reperfusion injury in mice with fatty liver disease. Hepatology. 2004;40:933–41.PubMed

64.

Fernandez L, Carrasco-Chaumel E, Serafin A, Xaus C, Grande L, Rimola A, et al. Is ischemic preconditioning a useful strategy in steatotic liver transplantation? Am J Transpl. 2004;4:888–99.

65.

Bessems M, Doorschodt BM, Kolkert JLP, Vetelainen RL, Van Vliet AK, Vreeling H, et al. Preservation of steatotic livers: a comparison between cold storage and machine perfusion preservation. Liver Transpl. 2007;13:497–504.PubMed

66.

Vairetti M, Ferrigno A, Carlucci F, Tabucchi A, Rizzo V, Boncompagni E, et al. Subnormothermic machine perfusion protects steatotic livers against preservation injury: a potential for donor pool increase? Liver Transpl. 2009;15:20–9.PubMed

67.

Jamieson RW, Zilvetti M, Roy D, Hughes D, Morovat A, Coussions CC, et al. Hepatic steatosis and normothermic perfusion-preliminary experiments in a porcine model. Transplantation. 2011;92:289–95.PubMed

68.

Minor T, Akbar S, Tolba R, Domobrowski F. Cold preservation of fatty liver grafts: prevent of functional and ultrastructual impairments by venous oxygen persufflation. J Hepatol. 2000;32:105–11.PubMed

69.

Minor T, Stegemann J, Hirner A, Koetting M. Impaired autophagic clearance after cold preservation of fatty livers correlates with tissue necrosis upon reperfusion and is reversed by hypothermic reconditioning. Liver Transpl. 2009;15:798–805.PubMed

70.

Koetting M, Luer B, Efferz P, Paul A, Minor T. Optimal time for hypothermic reconditioning of liver grafts by venous systemic oxygen persufflation in a large animal model. Transplantation. 2011;91:42–7.PubMed

71.

Minor T, Koetting M, Koetting M, Kaiser G, Efferz P, Luer B, et al. Hypothermic reconditioning by gaseous oxygen improves survival after liver transplantation in the pig. Am J Transpl. 2011;11:2627–34.

72.

Srinivasan PK, Yagi S, Doorschodt B, Nagai K, Afify M, Uemoto S, et al. Impact of venous systemic oxygen persufflation supplemented with nitric oxide gas on cold-stored, warm ischemia-damaged experimental liver grafts. Liver Transpl. 2012;18:219–25.PubMed

73.

Nagai K, Yagi S, Afify M, Bleilevens C, Uemoto S, Tolba RH. Impact of venous-systemic oxygen persufflation with nitric oxide gas on steatotic grafts after partial orthotopic liver transplantation in rats. Transplantation. 2013;95:78–84.PubMed

74.

Seifalian AM, Chidambaram V, Rolles K, Davidson BR. In vivo demonstration of impaired microcirculation in steatotic human liver grafts. Liver Transpl Surg. 1998;4:71–7.PubMed

75.

Ijaz S, Yang W, Winslet MC, Seifalian AM. Impairment of hepatic microcirculation in fatty liver. Microcirculation. 2003;10:447–56.PubMed

76.

Yamagami K, Enders G, Schauer RJ, Leiderer R, Hutter J, Yamamoto Y, et al. Heat-schock preconditioning protects fatty livers in genetically obese zucker rats from microvascular perfusion failure after ischemia reperfusion. Transpl Int. 2003;16:554–61.

77.

El-Badry AM, Moritz W, Contaldo C, Tian Y, Graf R, Clavien PA. Prevention of reperfusion injury and microcirculatory failure in macrosteatotic mouse liver by omega-3 fatty acids. Hepatology. 2007;45:855–63.PubMed

78.

El-Badry AM, Jang JH, Elsherbiny A, Contaldo C, Tian Y, Raptis DA, et al. Chemical composition of hepatic lipids mediates reperfusion injury of the macrosteatotic mouse liver through thromboxane A2. J Hepatol. 2011;55:1291–9.PubMed

79.

Zhang JX, Bauer M, Clemens MG. Vessel- and target cell-specific actions of endothelin-1 and endothelin-3 in rat liver. Am J Physiol. 1995;269:G269–77.PubMed

80.

Mizunuma K, Ohdan H, Tashiro H, Fudaba Y, Ito H, Asahara T. Prevention of ischemia–reperfusion-induced hepatic microcirculatory disruption by inhibiting stellate cell contraction using rock inhibitor. Transplantation. 2003;75:579–86.PubMed

81.

Ikeda F, Terajima H, Shimamura Y, Kondo T, Yamaoka Y. Reduction of hepatic ischemia/reperfusion-induced injury by a specific rock/rho kinase inhibitor y-27632. J Surg Res. 2003;109:155–60.PubMed

82.

Kuroda S, Tashiro H, Igarashi Y, Tanimoto Y, Nambu J, Oshita A, et al. Rho inhibitor prevents ischemia–reperfusion injury in rat steatotic liver. J Hepatol. 2012;56:146–52.PubMed

83.

Fondevila C, Shen XD, Duarte S, Busuttil RW, Coito AJ. Cytoprotective effects of acyclic RGD peptide in steatotic liver cold ischemia and reperfusion injury. Am J Transpl. 2009;9:2240–50.

84.

Hasegawa T, Ito Y, Wijeweera J, Liu J, Malle E, Farhood A, et al. Reduced inflammatory response and increased microcirculatory disturbances during hepatic ischemia–reperfusion injury in steatotic livers of ob/ob mice. Am J Physiol Gastrointest Liver Physiol. 2007;292:G1385–95.PubMed

85.

Yamagami K, Hutter J, Yamamoto Y, Schauer RJ, Enders G, Leiderer R, et al. Synergistic effects of brain death and liver steatosis on the hepatic microcirculation. Transplantation. 2005;80:500–5.PubMed

86.

Wakai T, Shirai Y, Sakata J, Korita PV, Ajioka Y, Tatakeyama K. Surgical outcomes for hepatocellular carcinoma in nonalcoholic fatty liver disease. J Gastrointest Surg. 2011;15:1450–8.PubMed

87.

Reddy SK, Marsh W, Varley PR, Mock BK, Chopra KB, Geller DA, et al. Underlying steatohepatitis, but not simple hepatic steatosis, increase morbidity after liver resection: case–control study. Hepatology. 2012;56:2221–30.PubMed

88.

Jamagin WR, Gonen M, Fong Y, DeMatteo R, Ben-Porat L, Little S, et al. Improvement in perioperative outcome after hepatic resection. Ann Surg. 2002;236:397–407.

89.

Cho JY, Suh KS, Kwon CH, Yi NJ, Lee KU. Mild hepatic steatosis is not a major risk factor for hepatectomy and regenerative power is not impaired. Surgery. 2006;139:508–15.PubMed

90.

Nagai S, Fujimoto Y, Kamei H, Nakamura T, Kiuchi T. Mild hepatic marovesicular steatosis may be a risk factor for hyperbilurubinemia in living liver donors following right hepatectomy. Br J Surg. 2009;96:437–44.PubMed

91.

Behrns K, Tsiotos G, DeSouza NF, Krishna MK, Ludwig F, Nagorney DM. Hepatic steatosis as a potential risk for major hepatic surgery. J Gastrointest Surg. 1998;2:292–8.PubMed

92.

de Meijer VE, Kalish BT, Puder M, Ijzermans JNM. Systemic review and meta-analysis of a steatosis as a risk factor in major hepatic resection. Br J Surg. 2010;97:1131–339.

93.

McCormack L, Dutkowski P, El-Badry AM, Clavien PA. Liver transplantation using fatty livers: always feasible? J Hepatol. 2011;54:1055–62.PubMed

94.

Doyle MBM, Vachharajani N, Wellen JR, Anderson CD, Lowell JA, Shenoy S, et al. Short-and long-term outcomes after steatotic liver transplantation. Arch Surg. 2010;145:653–60.PubMed

95.

McCormack L, Petrowsky H, Jochum W, Mullhaupt B, Weber M, Clavien PA. Use of severely steatotic grafts in liver transplantation: a matched case-control study. Ann Surg. 2007;246:940–8.PubMed

96.

Spitzer AL, Lao OB, Dick AAS, Bakthavatsalam R, Halldorson JB, Yeh MM, et al. The biopsied donor liver: incorporating macrosteatosis into high-risk donor assessment. Liver Transpl. 2010;16:874–84.PubMed

97.

Soejima Y, Shimada M, Suehiro T, Kishikawa K, Yoshimizu T, Hashimoto K, et al. Use of steatotic graft in living-donor liver transplantation. Transplantation. 2003;76:344–8.PubMed

98.

Hayashi M, Fujii T, Kiuchi T, Uryuhara K, Kasahara M, Takatsuki M, et al. Effects of fatty filtration of the graft on the outcome of living-related liver transplantation. Transplant Proc. 1999;31:403.PubMed

99.

Yoong KF, Gunson BK, Neil DAH, Mirza DF, Mayer AD, Buckels JA, et al. Impact of donor liver microvesicular steatosis on the outcome of liver transplantation. Transpl Proc. 1999;31:550–1.

100.

Cho JY, Suh KS, Lee HW, Cho EH, Yang SH, Cho YB, et al. Hepatic steatosis is associated with intrahepatic cholestasis and transient hyperbilirubinemia during regeneration after living donor liver transplantation. Transpl Int. 2006;19:807–13.PubMed

101.

Oshita A, Tashiro H, Amano H, Kobayashi T, Onoe T, Ide K, et al. Safety and feasibility of diet-treated donors with steatotic livers at the initial consultation for living-donor liver transplantation. Transplantation. 2012;93:1024–30.PubMed

102.

Nakamuta M, Morizono S, Soejima Y, Yoshizumi T, Aishima S, Takaugi S, et al. Short-term intensive treatment for donors with hepatic steatosis in living-donor liver transplantation. Transplantation. 2005;80:608–12.PubMed

103.

Clavien PA, Selzner M, Rudiger HA, Graf R, Kadry Z, Rousson V, et al. A prospective randomized study in 100 consecutive patients undergoing major liver resection with versus without ischemic preconditioning. Ann Surg. 2003;238:843–52.PubMedCentralPubMed

104.

Domart MC, Esposti DD, Sebagh M, Olaya N, Harper F, Pierron G, et al. Concurrent induction of necrosis, apoptosis, and autophagy in ischemic preconditioned human livers formerly treated by chemotherapy. J Hepatol. 2009;51:881–9.PubMed

105.

Scatton O, Zalinski Z, Jegou D, Compagnon P, Lesurtel M, Belghiti J, et al. Randomized clinical trial ischaemic preconditioning in major liver resection with intermittent pringle manoeuvre. Br J Surg. 2011;98:1236–43.PubMed

106.

Beck-Schimmer B, Breitenstein S, Urech S, De Conno E, Wittlinger M, Puhan M, et al. A randomized controlled trial on pharmacological preconditioning in liver surgery using volatile anesthetic. Ann Surg. 2008;248:909–18.PubMed

107.

Azoulay D, del Gaudio M, Andreani P, Ichai P, Sebag M, Adam R, et al. Effects of 10 minutes of ischemic preconditioning of cadaveric liver on the grafts preservation and function: the ying and the yang. Ann Surg. 2005;242:133–9.PubMedCentralPubMed

108.

Amador A, Grande L, Marti J, Deulofeu R, Miquel R, Sola A, et al. Ischemic pre-conditioning in deceased donor liver transplantation: a prospective randomized clinical trial. Am J Transpl. 2007;7(9):2180–9.

109.

Jassem W, Fuggle S, Thompson R, Arno M, Taylor J, Byrne J, et al. Effect of ischemic preconditioning on the genomic response to reperfusion injury in deceased donor liver transplantation. Liver Transpl. 2009;15:1750–65.PubMed

110.

Koneru B, Shareef A, Dikdan G, Desai K, Klein KM, Peng B, et al. The ischemic preconditioning paradox in deceased donor liver transplantation—evidence from a prospective randomized single blind clinical trial. Am J Transpl. 2007;7:2788–96.

111.

Guarrera JV, Henry SD, Samstein B, Odeh-Ramadan R, Kinkhabwala M, Goldstein MJ, et al. Hypothermic machine preservation in human liver transplantation. Am J Transpl. 2009;10:372–81.

112.

Henry SD, Nachber E, Tulipan J, Stone J, Bae C, Reznik L, et al. Hypothermic machine preservation reduces molecular markers of ischemia/reperfusion injury in human liver transplantation. Am J Transpl. 2012;12:2477–86.

113.

Op den Dries S, Karimian N, Sutton ME, Westerkamp AC, Nijsten MWN, Gouw ASH, et al. Ex vivo normothermic machine perfusion and viability testing of discarded human donor livers. Am J Transpl. 2013;13:1327–35.

114.

Treckmann J, Minor T, Saad S, Ozcelik A, Malago M, Broelsh CE, et al. Retrograde oxygen persuflation preservation of human livers: a pilot study. Liver Transpl. 2008;14:358–64.PubMed

115.

Minor T, Putter C, Gallinat A, Ose C, Kaiser G, Scherag A, et al. Oxygen persufflation as adunct in liver preservation (OPAL): study protocol for a randomized controlled trial. Trials. 2011;12:234.PubMedCentralPubMed

Titel: Ischemia–reperfusion injury in patients with fatty liver and the clinical impact of steatotic liver on hepatic surgery
verfasst von: Hirotaka Tashiro
Shintaro Kuroda
Yoshihiro Mikuriya
Hideki Ohdan
Publikationsdatum: 01.09.2014
Verlag: Springer Japan
Erschienen in: Surgery Today / Ausgabe 9/2014
Print ISSN: 0941-1291
Elektronische ISSN: 1436-2813
DOI: https://doi.org/10.1007/s00595-013-0736-9

Leitlinien kompakt für die Allgemeinmedizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Facharzt-Training Allgemeinmedizin

Die ideale Vorbereitung zur anstehenden Prüfung mit den ersten 24 von 100 klinischen Fallbeispielen verschiedener Themenfelder

Mehr erfahren

Neu im Fachgebiet Allgemeinmedizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Metformin rückt in den Hintergrund

24.04.2024 DGIM 2024 Kongressbericht

Es hat sich über Jahrzehnte klinisch bewährt. Doch wo harte Endpunkte zählen, ist Metformin als alleinige Erstlinientherapie nicht mehr zeitgemäß.

Myokarditis nach Infekt – Richtig schwierig wird es bei Profisportlern

24.04.2024 DGIM 2024 Kongressbericht

Unerkannte Herzmuskelentzündungen infolge einer Virusinfektion führen immer wieder dazu, dass junge, gesunde Menschen plötzlich beim Sport einen Herzstillstand bekommen. Gerade milde Herzbeteiligungen sind oft schwer zu diagnostizieren – speziell bei Leistungssportlern.

Update Allgemeinmedizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2014

A luteinizing hormone-releasing hormone agonist plus an aromatase inhibitor as second-line endocrine therapy in premenopausal females with hormone receptor-positive metastatic breast cancer

Treatment of the postoperative recurrence of lung cancer in octogenarians

Outcome of sentinel lymph node biopsy in breast cancer using dye alone: a single center review with a median follow-up of 5 years

Randomized controlled trial of the LigaSure vessel sealing system versus conventional open gastrectomy for gastric cancer

Positive clinical outcomes of the saphenous vein interposition technique for ruptured popliteal artery aneurysm

Spirometric and radiological evaluation of the remnant lung long after major pulmonary resection: can compensatory phenomena be recognized in clinical cases?